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The transcription factor, Runx2, promotes chondrocyte hypertrophy, whereas parathyroid hormone-related protein (PTHrP) delays this process.
To examine whether PTHrP suppresses chondrocyte hypertrophy via Runx2-dependent or -independent pathways, Runx2 expression and
chondrocyte differentiation were analyzed using bones from embryonic limbs of wild type and Runx2(−/−) mice. Treatment of cultured rudiments
with PTH dramatically suppresses Runx2 mRNA levels in hypertrophic chondrocytes. PTH-induced delay of chondrocyte hypertrophy was
observed in cultured tibiae from both Runx2(−/−) and wild-type embryos. This delay was also seen after PTH administration to limbs from wild type
and Runx2(−/−) mice expressing Runx2 in chondrocytes via a collagen 2 promoter-driven transgene. To further explore Runx2-dependent and
-independent effects of PTHrP, we examined embryonic tibiae and femurs from littermates null for PTHrP, Runx2, or both genes. Runx2(−/−)
femurs exhibited no vascular invasion or chondrocytes expressing collagen type X or osteopontin mRNA. In contrast, Runx2(−/−)/PTHrP(−/−)
mice exhibited limited vascular invasion and some chondrocytes expressing collagen X or osteopontin mRNA. In both tibia and femur, Runx2(−/−)/
PTHrP(−/−) mice exhibited expanded regions of proliferating chondrocytes when compared to the same regions in PTHrP(−/−) mice. These data
indicate that the delayed hypertrophy induced by PTHrP is mediated by both Runx2-dependent and -independent mechanisms.
© 2006 Elsevier Inc. All rights reserved.Keywords: PTH/PTHrP receptor; PTHrP; Runx2; Chondrocyte differentiationIntroduction
Targeted disruption of either PTHrP or PTH/PTHrP receptor
(PTHR) genes in vivo leads to early cessation of chondrocyte
proliferation and subsequent acceleration of chondrocyte
differentiation (Karaplis et al., 1994; Kobayashi et al., 2002;
Lanske et al., 1996). In contrast, overexpression of PTHrP in
nonhypertrophic chondrocytes maintains chondrocyte prolifer-
ation and inhibits chondrocyte maturation (Weir et al., 1996).
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doi:10.1016/j.ydbio.2005.12.044proliferation and causes a delay in chondrocyte differentiation
(Schipani et al., 1997). Furthermore, addition of PTH or PTHrP
to cultured metatarsals stimulates chondrocyte proliferation and
delays chondrocyte hypertrophy (Guo et al., 2002). Thus, PTHrP
acts through the PTHR to delay chondrocyte hypertrophy.
The molecular mediators of PTHR action are largely
unknown. One candidate is Runx2, a member of the core
binding factor (Cbf) family of heterodimeric transcription
factors (Ducy et al., 1997; Li et al., 2002; Okuda et al., 1996;
Wang et al., 1996). Cbf consists of two subunits, α and β. Three
mammalian genes encoding α subunits have been identified,
termed Cbfa1/Runx2/AML3/PEBP2αA, Cbfa2/Runx1/AML1/
PEBP2αB, and Cbfa3/Runx3/AML2/PEBP2αC (Ito, 1996;
Levanon et al., 1994), whereas only a single β subunit gene
(Cbfb/PEBP2β) with several spliced mRNAs is present in
mammals (Ogawa et al., 1993; Wang et al., 1993). Runx2,
initially noted to be essential for osteoblast development, also
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al., 1997; Otto et al., 1997). Runx2 expression accelerates
chondrocyte hypertrophy. Runx2(−/−) mice lack hypertrophic
chondrocytes in some skeletal elements such as femur and
humerus (Inada et al., 1999). Targeted expression of Runx2 in
nonhypertrophic chondrocytes accelerates chondrocyte differ-
entiation, rescues the chondrocyte phenotype in Runx2(−/−)
mice, and even leads to maturation of chondrocytes that do not
normally become hypertrophic (Takeda et al., 2001; Ueta et al.,
2001). Overexpression of a dominant negative Runx2 in
nonhypertrophic chondrocytes suppresses chondrocyte matura-
tion (Takeda et al., 2001; Ueta et al., 2001). Deletion of Runx3
has modest effects on chondrocyte maturation, and the double
deletion of both Runx2 and Runx3 leads to complete absence of
chondrocyte maturation (Yoshida et al., 2004).
Because the effect of Runx2 on chondrocyte differentiation
is opposite to that of PTHrP, we considered the possibility that
the delayed differentiation induced by PTHR activation might
be mediated in part by downregulation of Runx2 expression. To
examine this possibility, we employed an organ culture model
(Guo et al., 2002) that allows chondrocyte differentiation in the
context of the endochondral growth plate, and we also studied
genetic interactions of PTHrP and Runx2 in vivo. Here, we
show that PTHrP can dramatically and specifically down-
regulate Runx2 mRNA and protein in chondrocytes, and that
ablation of Runx2 can partially reverse the early differentiation
of the PTHrP(−/−) growth plate, but that PTHrP can also
influence chondrocyte differentiation and proliferation even in
the absence of Runx2.
Materials and methods
Reagents
All chemicals were obtained from Sigma-Aldrich Corp. unless otherwise
indicated. Rat PTH(1-34) amide was synthesized in the Biopolymer Core
Laboratory of the Endocrine Unit, Massachusetts General Hospital.
Mouse mutants
The coll II-driven Runx2 transgenic mouse has been in C57BL6 for more
than 3 generations; all other mice have been back crossed in C57BL6 for at least
8 generations.
Mouse embryonic metatarsals, tibia and femur culture
Embryonic metatarsals, tibia and femur from wild type or Runx2 knockout
mice (Otto et al., 1997) with or without the Runx2 transgene in chondrocytes
(Takeda et al., 2001), were dissected under sterile conditions and cultured in α-
MEM medium without nucleosides (Gibco BRL, Grand Island, NY),
supplemented with 0.1% inactivated fetal bovine serum and antibiotics (50 U/
ml of penicillin and 50μg/ml of streptomycin, Gibco BRL, Grand Island, NY).
Each rudiment was cultured in 500 μl of medium in a separate well of a 24-well
plate for up to 8 days and treated with vehicle or rat PTH1-34 (100 nM) for a
various period of culture.
Histologic and in situ hybridization analysis
For histologic analysis, cultured rudiments were fixed with 10% formalin
and then 70% ethanol. Paraffin blocks were prepared by standard histological
procedures. Paraffin sections were stained with hematoxylin and eosin. In situhybridizations were performed in paraffin sections using complementary 35S-
labeled riboprobes transcribed from plasmids encoding mouse Runx2, rat type II
collagen, mouse type X collagen, rat alkaline phosphatase, mouse collagenase 3,
mouse osteopontin, rat PTH/PTHrP receptor, and mouse Indian hedgehog. After
hybridization, sections were count-stained with hematoxylin and eosin. All
plasmids used in the present study were kindly provided by Dr. Ernestina
Schipani in our Unit.
Analysis of BrdU incorporation
Pregnant mice at the embryonic day18.5 were injected intraperitoneally with
100 μg bromodeoxyuridine (BrdU) and 12 μg fluorodeoxyuridine (FdU) per
gram of body weight 2 h before sacrifice. Embryos were fixed and embedded in
paraffin. Sections (5 μm) containing tibial and femur growth plates were used
for immunodetection of BrdU, according to the manufacturer's protocols
(Zymed Laboratories Inc., South San Francisco, California). To determine the
rate of cell proliferation, photomicrographs were taken at a 100× magnification,
and labeled and unlabeled chondrocytes were counted in the periarticular
proliferating and columnar proliferating zones of the growth plate. Cells in three
adjacent sections from two to three independent mice of identical genotype were
scored. The boxes that define each region for purposes of counting were drawn
guided by histology and in situ hybridization of chondrocyte markers such as
type X collagen in adjacent sections. Differences in percentages of labeled
nuclei were assessed using Student's t test.
Quantitative real-time PCR and Western blot
Total RNA for quantitative, real-time PCR and protein for Western blot
were extracted from cultured rudiments using Trizol reagents (Invitrogen,
Carlsbad, CA) according to manufacturer's protocol. For quantitative real-
time PCR, cDNA was prepared with random primer using SuperScript First-
Strand Systhesis System for RT-PCR (Invitrogen) and analyzed in
quadruplicate with the SYBR GreenMaster Mix (Qiagen) for 15 min at
95°C for initial denaturing, followed by 40 cycles of 95°C for 20 s, 60°C for
20 s, 72°C for 20 s, and 79°C for 5 s in the thermal cycler (MJ Research
Incorporated) with two sets of primers specific for endogenous and transgenic
Runx2 (Takeda et al., 2001). Primary rabbit antibody for Runx2 (Oncogene
Research Products, San Diego, CA) was used at a dilution of 1:500. This
antibody detects proteins of 65 and 60 kDa specific for Runx2. Second
antibody (horseradish peroxidase-conjugated goat anti-rabbit IgG) was used at
a dilution of 1:2000. Immunoreactivity was determined using the ECL chemi-
luminescence reaction (Amersham Biosciences).Results
No hypertrophic differentiation in Runx2(−/−) metatarsals and
femur ex vivo
Chondrocyte differentiation is delayed or severely disturbed to
a variable degree in bones formed by endochondral development
in Runx2(−/−) mice (Inada et al., 1999; Takeda et al., 2001).
Runx2(−/−) femurs exhibit no hypertrophic differentiation, while
hypertrophic differentiation is relatively normal in Runx2(−/−)
tibia. To further examine the role of Runx2 in chondrocyte
differentiation at early stages of endochondral development, we
performed ex vivo experiments with cultured embryonic
metatarsals isolated from Runx2(−/−) mice and wild-type
littermates. In this ex vivo culture model, the in vivo process of
proliferation and differentiation of chondrocytes is replicated and
can be acutely manipulated (Guo et al., 2002). Fig. 1 shows that
the Runx2(−/−) metatarsals are strikingly defective in their
differentiation in vitro. When Runx2(−/−) E14.5 metatarsals
were cultured in serum-free medium for up to 6 days, no
Fig. 1. No hypertrophic differentiation in Runx2(−/−) metatarsals ex vivo. Serial microscopic images (49×), as recorded by serial photomicrographs taken through an
inverted microscope, of E14.5 metatarsals from wild-type (+/+) or Runx2(−/−)(−/−) mice cultured in serum-free medium alone (control) or in the presence of rat PTH
(1-34) at a dose of 100 nM for up to 6 days, as indicated. In situ hybridization (bottom of the panel) of serial sections of 6-day cultured rudiments for collagen type X
mRNA (Coll. X, bright field, counter-stained with hematoxylin/eosin, and dark field) or collagen type II mRNA (Coll. II, dark field), as indicated.
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sion) and no cells expressing collagen type X mRNA were
seen, in contrast to the normal patterns in wild-type control
rudiments. The cultured Runx2(−/−) femur exhibited a similar
dramatic delay in hypertrophy (Fig. 2b), while the Runx2(−/−)
tibia exhibited a somewhat less dramatic delay (Fig. 2a).
Although messenger RNAs for Ihh and PTHR, markers for
prehypertrophic chondrocytes, could be detected in Runx2(−/−)
tibia cultured for 24 h, almost no cells that expressed either
osteopontin or collagen type X mRNAs, markers for
hypertrophic chondrocytes, were observed in the Runx2 mutant
(Fig. 2a). A more severe abnormality in hypertrophic
differentiation was found in the Runx2(−/−) femur of the
same embryo, in which even markers of prehypertrophic
chondrocytes such as Ihh and PTHR mRNAs were absent (Fig.
2b). These results are consistent with those observed in vivo
and indicate that Runx2 stimulates chondrocyte maturation in
the endochondral growth plate.
When the wild-type metatarsal was treated with PTH,
chondrocyte hypertrophy was completely blocked, in a way
that is similar to that observed in vehicle-treated Runx2(−/−)
metatarsals (Fig. 1). These data suggest the possibility that
suppression of Runx2 action might mediate, in part, the effects
of PTHR activation on chondrocytes.PTH downregulates Runx2 mRNA in a time-dependent manner
If PTHrP suppresses Runx2 action, it could do so either by
decreasing the levels of Runx2 mRNA or protein or by
blocking the actions of Runx2. Runx2 mRNA is expressed in
hypertrophic chondrocytes and in perichondral cells surround-
ing the layers of columnar proliferating and hypertrophic
chondrocytes and, to a lesser degree, in proliferating
chondrocytes (Fig. 3). To examine the acute effect of PTH
(a surrogate for PTHrP) on Runx2 mRNA expression in
chondrocytes, cultured tibiae or femurs at E14.5 were treated
with PTH for the last 6 h of a 24-h culture. Runx2 mRNA
expression then was analyzed by in situ hybridization. As
shown in Figs. 3a, b, Runx2 mRNA expression in both tibiae
and femurs, seen as white spots in the dark field, was
dramatically decreased by PTH in chondrocytic cells that
expressed type X collagen and/or osteopontin mRNAs, but
not in the perichondral cells, which represent precursors of
osteoblasts. Because Runx3 can complement some actions of
Runx2 (Yoshida et al., 2004), the effect of PTH on the
expression pattern of Runx3 mRNA was assessed. Runx3
mRNA was widely expressed in all chondrocyte groups and
the perichondrium of tibiae at E14.5 (Fig. 3b). PTH
administration did not change that expression. These data
Fig. 2. A delay in chondrocyte hypertrophy of Runx2(−/−) tibia and femur. E14.5 tibiae (a) or femurs (b) were isolated from littermates of wild-type (+/+) and
Runx2(−/−) embryos and cultured for 24 h. In situ hybridization of serial sections was performed for Coll II and X, osteopontin (OP), Indian hedgehog (Ihh), and
PTHR, as indicated. Histological photomicrographs were taken in dark field at 40× (a) or 100× (b) magnifications.
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ger RNA specifically in the hypertrophic chondrocytes. This
inhibitory effect was further shown to occur in a time-
dependent manner, with the maximal effect of PTH on Runx2
mRNA expression noted after 8 h of the treatment (Fig. 4).
Conversely, treatment with PTH significantly enhanced an
expression of osteopontin mRNA in hypertrophic chondro-
cytes (Fig. 3b); the maximal effect was observed after 4 h of
treatment (Fig. 4). This reciprocal regulation of Runx2 and
osteopontin mRNAs by PTH in the same cells suggests that
the fall in Runx2 mRNA is not a nonspecific, toxic effect of
PTH. Further, this suppression of Runx2 mRNA levels might
mediate, in part, the suppression of chondrocyte maturation
by PTHrP.
Functional Runx2 protein is not required for PTH suppression
of Runx2 mRNA
Runx2 regulates several genes expressed in osteoblasts
and chondrocytes, including those encoding osteocalcin,
osteopontin, bone sialoprotein, collagen α1(I), and MMP13(Ducy et al., 1997; Otto et al., 2003). In transfected cells,
Runx2 has been shown to either stimulate (Ducy et al.,
1999) or inhibit transcription of the Runx2 gene itself (Drissi
et al., 2000).Further, Runx2 has been shown to mediate at
least in part the activation of the collagenase 3 gene by PTH
in osteoblasts (Selvamurugan et al., 2000). To see whether a
transcriptional activity of Runx2 is similarly essential for
PTH regulation of Runx2 mRNA, we examined the effect of
PTH on Runx2 mRNA expression in cultured rudiments
isolated from Runx2(−/−) embryos. Runx2 mRNA could be
detected in the Runx2(−/−) mice because Runx2 gene
disruption was accomplished by insertion of a selection
cassette into the exon containing the Q/A repeat domain of
the gene without blocking production of stable, nonfunc-
tional mRNA (Otto et al., 1997). Treatment with rat PTH
greatly decreased mutated Runx2 mRNA in chondrocytes of
Runx2(−/−) rudiments, and this inhibition was comparable to
that observed in the rudiments isolated from wild-type
littermates (Fig. 3c). These data suggest that the transcrip-
tional activity of Runx2 protein is not required for Runx2
mRNA repression induced by PTHR.
Fig. 3. Effect of PTH on Runx2 and osteopontin mRNA expression in chondrocytes. (a) In situ hybridization for Runx2 mRNAwas performed in E14.5 tibiae and
femurs isolated from wild-type embryos and treated with vehicle or rat PTH (1–34) at 100 nM for the last 6 h of 24-h culture. (b) In situ hybridization for Coll.II and X,
OP, Runx3, and Runx2 mRNAs in serial sections of E14.5 tibias isolated from wild-type embryo and treated with vehicle or rat PTH (1–34) at 100 nM for the last 8 h
of 24-h culture. All photomicrographs are taken in dark field at 40× magnification. Similar observation was made in three independent experiments. (c) Dark field
photomicrographs (40×) of in situ hybridization for Runx2 mRNA in sections of E14.5 tibiae, isolated from wild-type (+/+) and Runx2(−/−) littermates and treated
with vehicle or rat PTH (1–34) at 100 nM for the last 8 h of the 24-h culture, as indicated.
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differentiation
Disruption of the PTHrP gene in vivo causes acceleration
of chondrocyte differentiation (Karaplis et al., 1994). Because
activation of the PTHR leads to a fall in Runx2 mRNA, it is
possible that the fall in Runx2 mRNA mediates at least partly
the action of PTHrP on the growth plate. At the same time,
PTHrP may also accomplish these actions through other
mechanisms. To explore these possibilities, we examined the
impact of Runx2 ablation on cartilage development in the
absence of PTHrP in vivo. To the extent that suppression of
Runx2 expression mediates the actions of PTHrP, we would
expect that ablation of Runx2 expression would reverse the
consequences of ablation of PTHrP expression. One would
also expect that ablation of PTHrP expression would have no
effect on chondrocyte differentiation in bones of Runx2(−/−)
mice. To test these hypotheses, PTHrP(+/−); Runx2(+/−)
mice were mated with each other, and tibiae and femurs ofthe progeny were studied at embryonic day 17.5. Fig. 5a
shows that, as expected, the domain of proliferating
chondrocytes, indicated by brackets, is shortened in the
PTHrP(−/−) tibia, when compared to the wild-type tibia. This
region that is shortened in the PTHrP(−/−) tibia is expanded
in the PTHrP(−/−); Runx2(−/−) tibia, but that this expansion
leaves the region of proliferating cells still considerably
shorter than the corresponding region in the wild-type tibia.
This partial “rescue” of the PTHrP(−/−) phenotype is
consistent with the idea that PTHrP's action to suppress
Runx2 mRNA partly explains the expansion of the growth
plate caused by PTHrP. However, Fig. 5a also shows that in
the absence of Runx2, hypertrophic differentiation in tibiae
was still accelerated by further disruption of the PTHrP gene.
Further, definite, though modest, hypertrophic differentiation
was observed in the double knockout mutant femur, even
though the Runx2(−/−) femur exhibited no hypertrophic
differentiation (Fig. 5b). Vascular invasion, as illustrated by
the presence of erythrocytes in the double knockout skeletal
Fig. 4. Time-dependent effect of PTH on gene expression. Dark field photomicrographs (40×) of in situ hybridization for osteopontin, Runx2 and collagen type X
mRNAs in serial sections of E14.5 femurs, isolated from wild-type embryos and treated with rat PTH (1–34) at 100 nM for varied periods of time (hours) during
culture, as indicated. Similar results were also observed in cultured tibiae at E14.5 (data not shown).
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type X and osteopontin mRNAs were observed in the double
knockout femur but not in Runx2(−/−) femur.
We further analyzed genetic interactions of PTHrP and Runx2
on chondrocyte hypertrophy in both tibia and femur at embryonic
day 18.5. The Runx2(−/−) femurs exhibited more dramatic
acceleration of hypertrophy after removal of one or both the
PTHrP alleles, as shown by a large expansion of cells that
express collagen type X mRNA (Fig. 6a). These data suggest that
Runx2 is not absolutely required for hypertrophic differentiation
that is regulated by PTHrP. Analogous shortening of the region of
proliferating chondrocytes (yellow arrow) with removal of the
PTHrP gene in the context of Runx2(−/−) was also seen in the
tibia (Fig. 6b). Moreover, the short chondrocyte columns of the
PTHrP(−/−) tibia and femur were progressively expanded with
concomitant deletion of one or both alleles of Runx2 (Fig. 6).
These findings, thus, further support the idea that PTHrP
regulates chondrocyte differentiation by both Runx2-dependent
and Runx2-independent mechanisms (shown by the partial
reversal of the PTHrP(−/−) phenotype with ablation of Runx2
and by the effects on hypertrophic chondrocytes in Runx2(−/−)
bones with ablation of PTHrP, respectively).
To further assess Runx2-dependent and Runx2-independent
actions of PTHrP on chondrocyte hypertrophy, we studied bones
from mice in which the suppression of Runx2 mRNA expression
in chondrocytes by PTHrP is not expected to occur. A transgene
which drives expression of Runx2 via the collagen II promoter
was introduced into both wild-type and Runx2(−/−) mice by
appropriate matings (Takeda et al., 2001). Metatarsals from these
mice were cultured in the presence or absence of PTH. Asexpected, in the absence of PTH treatment (“Vehicle”, Fig. 7a),
the Runx2-expressing transgene accelerated hypertrophy in the
wild-type context and induced hypertrophic differentiation
(indicated by the dark region of mineralization) not otherwise
seen in the Runx2(−/−) metatarsal. These morphologic findings
were confirmed by in situ hybridization for collagen II mRNA,
expressed in nonhypertrophic chondrocytes (Fig. 7b) and for
osteopontin, expressed in late hypertrophic chondrocytes (Fig.
7c). Interestingly, PTH treatment delayed this hypertrophic
differentiation, even though the Runx2-expressing transgene is
not expected to be regulated by PTH (Figs. 7a–c). To examine
the effect of PTH on expression of the transgene at both the
mRNA and protein level, we performed both quantitative real-
time PCR and Western blot analyses of the cultured metatarsals.
As expected, PTH treatment failed to downregulate Runx2
mRNA encoded by the transgene (Fig. 7d, hatched bars) in
contrast to the effect of PTH to suppress endogenous Runx2
mRNA (Fig. 7d, solid bars). Similarly, PTH suppressed the levels
of Runx2 protein in Runx2(+/−) metatarsals (Fig. 7e, “Tg (−)
Runx2(+/−)” comparing control (“CON”) to PTH treatment
(PTH”)) and failed to suppress the levels of Runx2 protein when
the transgene was expressed either in the context of a wild-type
(“Tg(+) Runx2 (+/+)”)or knockout (“Tg(+) Runx2(−/−)”)
background. It is noted that two closely spaced proteins of 60
and 65 kDa specific for Runx2 were not detected in Runx2(−/−)
bones (“Tg(−) Runx2(−/−) CON”); this result confirms the
specificity of the antiserum and the identity of the specific bands.
PTH treatment suppressed both Runx2 proteins in wild-type
metatarsals, whereas PTH treatment actually increased Runx2
proteins in the cultured rudiments expressing the Runx2
Fig. 5. Genetic interactions of Runx2 and PTHrP in vivo, E17.5. In situ hybridization of serial sections for collagen type X mRNA (both bright and dark fields in panel
a and dark field in panel b) and osteopontin (dark field in panel b). Tibiae (a, brackets indicate columnar layer of proliferating chondrocytes) or femurs (b, inset shows
high magnification of the indicated region, in which many erythrocytes are present in femur skeletal elements) were dissected from littermates of wild-type (+/+),
Runx2(−/−), PTHrP(−/−), or double knockout of Runx2 and PTHrP (double −/−) embryos at E17.5, as indicated. Histological photomicrographs were taken at 40× (a)
or 100× (b) magnifications, respectively.
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of chondrocytes expressing collagen II mRNA and thus the
collagen II promoter-driven transgene, after exposure to PTH.
These data indicate that PTH delays chondrocyte hypertrophy
even in the presence of substantial Runx2 expression.
Genetic interaction of PTHrP and Runx2 on rate and extent of
chondrocyte proliferation
PTHrP activation of the PTHR increases both the extent of the
compartment of proliferating chondrocytes (its length along the
major axis of the long bone) and, modestly, the rate of
proliferation of chondrocytes within that compartment (as
measured as the fraction of cells that incorporate a pulse of
BrdU within the compartment of proliferating chondrocytes).
Thus, ablation of either PTHrP or PTHR leads to a dramatic
reduction in the extent of the columns of proliferating
chondrocytes, though the effect of PTHrP ablation on the
fraction of proliferating chondrocytes that incorporate BrdU is
modest (Karp et al., 2000). The effect of Runx2 on chondrocyte
proliferation has not been extensively studied, though Yoshida et
al. (2004) report that proliferation of chondrocytes in E18.5 tibia
of Runx2(−/−) mice is decreased. The results in Figs. 5 and 6show that Runx2 and PTHrP interact to control the extent of the
proliferating region, defined morphologically and through the
expression of differentiation markers. It is possible, however, that
the expansion of nonhypertrophic chondrocytes that occurs when
Runx2 alleles are eliminated in the PTHrP(−/−) context might
occur without actual expansion of the domain of actively
proliferating cells. In that case, for example, a substantial region
of the flat cell layer might contain chondrocytes that no longer
proliferate but have not yet differentiated further to become
hypertrophic. To determine the interactions of PTHrP and Runx2
on the extent of the proliferative domain and to explore possible
interactions of these genes on the rate of chondrocyte
proliferation, BrdU was administered to pregnant mice bearing
litters of varying genotypes. As expected, in both the femur and
the tibia, the PTHrP(−/−) bones have much shorter regions of
nonhypertrophic chondrocytes than normal, defined morpholog-
ically (Fig. 8a, Tibia (H and E) with Runx2 present). Also, in the
Runx2(−/−) background, removal of PTHrP constricted the
extent of the nonhypertrophic domain (Fig. 8a, Tibia (H and E)
with Runx2 absent). The panels of tibia and femur after BrdU
labeling show that the extent of the proliferative region is cons-
tricted when PTHrP(−/−) bones are compared to PTHrP(+/+)
bones, both in the presence and in the absence of Runx2
Fig. 6. Genetic interactions of Runx2 and PTHrP in vivo, E18.5. Hematoxylin and eosin staining (H and E) and in situ hybridization for collagen type X mRNA (Coll.
X, dark field) from serial sections of femurs (in panel a) and tibiae (in panel b) at E18.5, as indicated. At least two animals of each genotype as indicated were examined
within three litters by mating of PTHrP(+/−); Runx2(+/−) mice. Histological photomicrographs were taken at 100× magnifications.
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Fig. 8b, see below, and also roughly outline the extent of BrdU
incorporation in each of these regions.) Further, just as the
Runx2(−/−); PTHrP(−/−) bones exhibit an expanded nonhy-
pertrophic region morphologically when compared to the
PTHrP(−/−) bones, the Runx2(−/−); PTHrP(−/−) bones also
exhibited an expanded region of proliferating chondrocytes that
incorporate BrdU when compared to PTHrP(−/−) bones. Thus,
the effects of PTHrP and Runx2 on the extent of the zone of
proliferating chondrocytes corresponds closely to the effects of
these genes on morphologic and genetic markers of chon-
drocyte differentiation.
Within the zone of proliferating chondrocytes, the effects of
the genetic interactions of PTHrP and Runx2 on the rate of
chondrocyte proliferation, however, were not all anticipated. As
previously reported (Karp et al., 2000), the PTHrP(−/−) bones at
E18.5 exhibited no change in the rate of chondrocyte
proliferation when compared to wild type (Fig. 8b, tibia andfemur). The Runx2(−/−) bones exhibited a modest but not
statistically significant decrease in chondrocyte proliferation
compared to wild type. In contrast, the rate of chondrocyte
proliferation was greatly decreased by removal one or both the
PTHrP alleles in the absence of Runx2. This result indicates a
Runx2-independent action of PTHrP on the rate of chondrocyte
proliferation. Further, in the absence of PTHrP, the proliferation
rate of both round and flat cells was dramatically reduced by a
loss of both Runx2 alleles. These findings suggest that PTHrP
and Runx2 can complement each other in the regulation of the
rate of chondrocyte proliferation, with effects of each gene seen
most dramatically in the absence of the other.
Discussion
Because PTHrP acts to delay the conversion of prolifer-
ating chondrocytes to post-proliferative prehypertrophic chon-
drocytes, while Runx2 and, to a lesser extent, Runx3 (Yoshida
Fig. 7. Effect of PTH on chondrocyte hypertrophy in the presence of Runx2 transgene. (a) Serial microscopic images (49×), taken through an inverted microscope, of
E15.5 metatarsals from wild type (+/+), wild type withCollII-driven Runx2 transgene (+/+ and Tg), or Runx2(−/−)with the transgene (−/− and Tg). All rudiments were
cultured for 3 days and treated with vehicle or rat PTH (1–34) at 100 nM for 24 to 48 h, as indicated. In situ hybridization of serial sections of rudiments cultured for 3
days for collagen II mRNA (Coll II) (b) or osteopontin (OP) mRNAs (c). All histological photomicrographs were taken at 100× magnifications. (d, e) Effect of PTH on
both endogenous and transgenic Runx2 expression. E14.5 metatarsals were isolated from littermates of Runx2(+/−), wild type with CollII-driven Runx2 transgene (+/+
and Tg), or Runx2(−/−)with the transgene (−/− and Tg) and treated with 100 nM rat PTH (1–34) for 8 days. Total RNA for quantitative real-time PCR (d, filled bar for
endogenous Runx2 mRNA and open bar for transgenic Runx2 mRNA; data were expressed as percentage of vehicle-treated sample) and protein for Western blot (e,
control samples labeled “CON”, PTH-treated samples labeled “PTH”) were extracted from the cultured rudiments using Trizol reagents, as described in the Materials
and methods.
124 J. Guo et al. / Developmental Biology 292 (2006) 116–128et al., 2004) are required for the differentiation of proliferating
chondrocytes to prehypertrophic and then hypertrophic
chondrocytes, we explored possible interactions of PTHrP
signaling and Runx2 expression/action. We found evidence
for both Runx2-dependent and Runx2-independent actions of
PTHrP and also found an unexpected interaction between
PTHrP and Runx2 in controlling the rate of chondrocyte
proliferation.
Runx2-dependent actions of PTHrP
In metatarsal cultures, PTHrP administration quickly and
dramatically leads to a fall of Runx2 mRNA and protein
expression in chondrocytes (Figs. 3, 4, and 7). This action
appears to be cell-type specific because Runx2 mRNA changedlittle in the preosteoblasts in the perichondrium of the same
bones. Iwamoto et al. (2003) and Li et al. (2004) recently
reported that PTHrP suppresses runx2 mRNA in secondary
cultures of fetal chick chondrocytes. Other reports have focused
on regulation of Runx2 mRNA and protein in models of
osteoblasts. In those reports, PTH or forskolin (like PTH, a
stimulator of adenylate cyclase) had either little effect on Runx2
mRNA or increased it in osteoblast-like cells. The action of
PTHrP to decrease levels of Runx2 mRNA and protein in
chondrocytes raises the possibility that this decrease may
mediate some of the actions of PTHrP on the growth plate.
Consistent with this hypothesis, we found that the constriction
of the extent of the domain of proliferating chondrocytes
found in the PTHrP(−/−) mouse is partially reversed in the
PTHrP(−/−); Runx2(−/−) mouse (Figs. 5, 6, and 8). This
Fig. 8. Effect of PTHrP and Runx2 on chondrocyte proliferation. BrdU was administered to pregnant mice 2 h prior to sacrifice at the gestational age of day 18.5. Histology (H&E) and immunohistochemical staining
(BrdU) subsequently was performed on sections of the proximal tibiae and the distal femurs from six different genotypes of embryos, as indicated. BrdU-positive nuclei are stained dark brown. All nuclei are
counterstained with hematoxylin. BrdU incorporation, calculated as percentage of BrdU-positive nuclei in the periarticular (Round) and columnar (Flat) proliferating chondrocytes, is shown graphically. Bars represent
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chondrocytes and the expanded domain of DNA synthesis
noted after administration of BrdU. Though the ex vivo data
suggest that at least part of this reversal results from the
actions of PTHrP to suppress Runx2 expression, further
experiments will be needed to determine how much of the in
vivo phenotype results from this action.
Runx2-independent actions of PTHrP
To determine whether the suppression of Runx2 mRNA and
protein can fully explain the action of PTH to suppress
differentiation in cultured metatarsals, we studied metatarsals in
which all of the Runx2mRNA and protein were generated using a
transgene driven by the collagen 2 promoter. As previously
reported for the femur in vivo (Inada et al., 1999, Takeda et al.,
2001), we found that the transgene drives hypertrophy of
chondrocytes in the metatarsals of Runx2(−/−) mice (Fig. 7).
Administration of PTH slows this differentiation, even though, as
expected, levels of Runx2 mRNA and protein did not decrease in
these bones. Thus, we can conclude that PTH (and presumably
PTHrP) can delay chondrocyte differentiation through Runx2-
independent mechanisms. This finding using metatarsal cultures
was confirmed by analysis of bones from mice missing PTHrP
and Runx2 alleles in various combinations (Figs. 5, 6). The femur
of Runx2(−/−) mice exhibits no hypertrophic chondrocytes or
expression of type X collagen mRNA at E17.5. In contrast, the
femur of Runx2(−/−); PTHrP(−/−) mice express small amounts
of both type X collagen mRNA and osteopontin mRNA, a
marker of late hypertrophic chondrocytes. Histologically, these
femurs show disorganized chondrocytes with the beginning of
hypertrophic morphology and signs of vascular invasion at the
margins of the bone. In the tibia and femur of E18.5 mice,
removal of one or both alleles of PTHrP similarly leads to
accelerated hypertrophy. The effect of removal of just one PTHrP
allele is particularly striking because heterozygosity for PTHrP
in the context of Runx2(+/+) has little discernible effect on
chondrocyte differentiation.
What mechanisms might explain the actions of PTHrP in the
Runx2(−/−) growth cartilage? One possible target gene might
be Runx3, since deletion of Runx3modestly delays chondrocyte
hypertrophy, and the Runx2(−/−); Runx3(−/−) mouse lacks all
chondrocyte differentiation (Yoshida et al., 2004). However,
PTH has no effect on Runx3mRNA in the tibia cultures (Fig. 3).
We cannot, however, eliminate the possibility that PTH lowers
Runx3 protein levels, since we lack an antibody needed to make
such a determination. Without affecting the levels of Runx
proteins, however, PTHrP, of course, might block the action of
Runx2 or Runx3 by interfering with gene activation (or
suppression) by these proteins. The ability of PTH administra-
tion to delay hypertrophy even in the presence of high levels of
Runx2 mRNA and protein (Fig. 7) suggests that PTHrP might
block the actions of Runx2 protein.
Further, PTHrP has actions that might be independent of
effects on Runx family members. PTHrP, through activation of
protein kinase A, leads to phosphorylation of SOX9 (Huang
et al., 2001). Since phosphorylated SOX9 activates transcrip-tion more effectively than unphosphorylated SOX9, and since
SOX9 acts to delay differentiation of chondrocytes, part of
PTHrP's action to delay chondrocyte differentiation is plausibly
mediated by phosphorylation of SOX9. Further, PTHrP lowers
levels of mRNA and protein encoding p57, the cdk inhibitor
(MacLean et al., 2004). Ablation of p57 reverses most of the
accelerated hypertrophy in PTHrP(−/−) mice, so the suppres-
sion of p57 mRNA and protein plausibly mediates some of the
action of PTHrP to delay chondrocyte hypertrophy. Before
concluding that the effects of PTHrP on SOX9 and p57
represent pathways completely independent of Runx2 action,
however, further studies are needed to determine possible
relationships between SOX9, p57, and Runx2 on chondrocyte
differentiation.
Interactions of PTHrP and Runx2 in regulating chondrocyte
proliferation
Both PTHrP and Runx2 individually have modest effects on
chondrocyte proliferation. The action of PTHrP is detectable in
vivo at E15.5 but is no longer detectable at E18.5 (Karp et al.,
2000; Fig. 8). Though Yoshida et al. (2004) noted an effect of
Runx2 ablation on chondrocyte proliferation, the modest effect
seen in the current experiments did not reach statistical
significance. Since the bones and stages of development were
comparable in the two studies, we cannot explain this
difference. Nevertheless, the dramatic decrease in proliferation
of chondrocytes in both the tibia and femur of Runx2(−/−) mice
missing either one or both PTHrP alleles was not expected. The
explanation for this gene interaction may well involve noncell
autonomous effects. For example, Ihh is increased in both the
femur and the tibia of the double knockout mice when
compared to the Runx2(−/−) mouse (data not shown). This
increase in Ihh expression would be expected to increase
chondrocyte proliferation and may explain why the double
knockout appears to have a slightly less severe proliferation
phenotype than that of the PTHrP(+/−); Runx2(−/−)mouse. We
can only speculate on the cause of the dramatic decrease in
chondrocyte proliferation in the PTHrP(+/−); Runx2(−/−)
mouse. One possible explanation involves the possible
interaction of Runx2 with the cell cycle regulator, Rb. In
osteoblasts, Runx2 associates with Rb, and this association
increases the transcriptional activity of Runx2 (Thomas et al.,
2001). One can speculate that in the Runx2(−/−) chondrocytes,
more Rb may be available for cell cycle regulation than in wild-
type chondrocytes. In that setting, regulators of Rb action might
have more prominent effects. Since PTHrP suppresses levels of
the cdk antagonist, p57, this suppression might allow cdks to
phosphorylate the increased levels of Rb and, thereby, have a
greater than normal effect on chondrocyte proliferation.
The effect of PTHrP gene ablation in the context of Runx2
gene ablation vividly illustrates how the rate of chondrocyte
proliferation (as measured by changes in rates of DNA
synthesis) and the extent of chondrocyte proliferation (as
measured by the length of the region of proliferating cells)
can be independently regulated. In the absence of PTHrP,
removal of Runx2 expands the region of proliferating
127J. Guo et al. / Developmental Biology 292 (2006) 116–128chondrocytes in both the tibia and in the femur (compare
Runx2(+/+); PTHrP(−/−) to Runx2(−/−); PTHrP(−/−) in Fig.
8). Yet, these bones with expanded growth plates have a
dramatic decrease in the rate of chondrocyte proliferation.
These findings emphasize that the capacity to proliferate is a
property of chondrocytes in one discrete stage of develop-
ment, and that the number of chondrocytes in this stage is
regulated independently from the regulation of the rate of
proliferation of chondrocytes.
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